Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

DRTS vs IART vs NVCR vs MDT

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
DRTS
Alpha Tau Medical Ltd.

Biotechnology

HealthcareNASDAQ • IL
Market Cap$691M
5Y Perf.-18.7%
IART
Integra LifeSciences Holdings Corporation

Medical - Devices

HealthcareNASDAQ • US
Market Cap$1.06B
5Y Perf.-80.4%
NVCR
NovoCure Limited

Medical - Instruments & Supplies

HealthcareNASDAQ • JE
Market Cap$1.92B
5Y Perf.-87.3%
MDT
Medtronic plc

Medical - Devices

HealthcareNYSE • IE
Market Cap$99.94B
5Y Perf.-34.0%

DRTS vs IART vs NVCR vs MDT — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
DRTS logoDRTS
IART logoIART
NVCR logoNVCR
MDT logoMDT
IndustryBiotechnologyMedical - DevicesMedical - Instruments & SuppliesMedical - Devices
Market Cap$691M$1.06B$1.92B$99.94B
Revenue (TTM)$0.00$1.64B$674M$35.48B
Net Income (TTM)$-43M$-496M$-173M$4.61B
Gross Margin39.6%75.2%61.9%
Operating Margin5.8%-27.2%17.9%
Forward P/E5.8x14.1x
Total Debt$14M$2.03B$290M$28.52B
Cash & Equiv.$16M$235M$103M$2.22B

DRTS vs IART vs NVCR vs MDTLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

DRTS
IART
NVCR
MDT
StockMar 21May 26Return
Alpha Tau Medical L… (DRTS)10081.3-18.7%
Integra LifeScience… (IART)10019.6-80.4%
NovoCure Limited (NVCR)10012.7-87.3%
Medtronic plc (MDT)10066.0-34.0%

Price return only. Dividends and distributions are not included.

Quick Verdict: DRTS vs IART vs NVCR vs MDT

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: MDT leads in 4 of 7 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Alpha Tau Medical Ltd. is the stronger pick specifically for recent price momentum and sentiment. IART and NVCR also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
DRTS
Alpha Tau Medical Ltd.
The Defensive Pick

DRTS is the #2 pick in this set and the best alternative if sleep-well-at-night and defensive is your priority.

  • Lower volatility, beta 1.72, Low D/E 17.8%, current ratio 7.45x
  • Beta 1.72, current ratio 7.45x
  • +188.6% vs MDT's -2.8%
Best for: sleep-well-at-night and defensive
IART
Integra LifeSciences Holdings Corporation
The Value Play

IART is the clearest fit if your priority is value.

  • Lower P/E (5.8x vs 14.1x)
Best for: value
NVCR
NovoCure Limited
The Growth Play

NVCR is the clearest fit if your priority is growth exposure.

  • Rev growth 8.3%, EPS growth 21.8%, 3Y rev CAGR 6.8%
  • 8.3% revenue growth vs DRTS's -115.8%
Best for: growth exposure
MDT
Medtronic plc
The Income Pick

MDT carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.

  • Dividend streak 36 yrs, beta 0.47, yield 3.6%
  • 26.5% 10Y total return vs DRTS's -22.3%
  • 13.0% margin vs IART's -30.1%
  • Beta 0.47 vs IART's 2.34, lower leverage
Best for: income & stability and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthNVCR logoNVCR8.3% revenue growth vs DRTS's -115.8%
ValueIART logoIARTLower P/E (5.8x vs 14.1x)
Quality / MarginsMDT logoMDT13.0% margin vs IART's -30.1%
Stability / SafetyMDT logoMDTBeta 0.47 vs IART's 2.34, lower leverage
DividendsMDT logoMDT3.6% yield; 36-year raise streak; the other 3 pay no meaningful dividend
Momentum (1Y)DRTS logoDRTS+188.6% vs MDT's -2.8%
Efficiency (ROA)MDT logoMDT175.8% ROA vs DRTS's -42.3%, ROIC 6.0% vs -46.5%

DRTS vs IART vs NVCR vs MDT — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

DRTSAlpha Tau Medical Ltd.

Segment breakdown not available.

IARTIntegra LifeSciences Holdings Corporation
FY 2025
Codman Specialty Surgical
73.4%$1.2B
Tissue Technologies
26.6%$435M
NVCRNovoCure Limited

Segment breakdown not available.

MDTMedtronic plc
FY 2025
Cardiac and Vascular Group
37.3%$12.5B
Neuroscience Group
29.4%$9.8B
Medical Surgical
25.1%$8.4B
Diabetes Group
8.2%$2.8B

DRTS vs IART vs NVCR vs MDT — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLMDTLAGGINGNVCR

Income & Cash Flow (Last 12 Months)

MDT leads this category, winning 3 of 6 comparable metrics.

MDT and DRTS operate at a comparable scale, with $35.5B and $0 in trailing revenue. MDT is the more profitable business, keeping 13.0% of every revenue dollar as net income compared to IART's -30.1%. On growth, NVCR holds the edge at +12.3% YoY revenue growth, suggesting stronger near-term business momentum.

MetricDRTS logoDRTSAlpha Tau Medical…IART logoIARTIntegra LifeScien…NVCR logoNVCRNovoCure LimitedMDT logoMDTMedtronic plc
RevenueTrailing 12 months$0$1.6B$674M$35.5B
EBITDAEarnings before interest/tax$18M$209M-$165M$9.4B
Net IncomeAfter-tax profit-$43M-$496M-$173M$4.6B
Free Cash FlowCash after capex-$33M-$10M-$48M$5.4B
Gross MarginGross profit ÷ Revenue+39.6%+75.2%+61.9%
Operating MarginEBIT ÷ Revenue+5.8%-27.2%+17.9%
Net MarginNet income ÷ Revenue-30.1%-25.7%+13.0%
FCF MarginFCF ÷ Revenue-0.6%-7.1%+15.2%
Rev. Growth (YoY)Latest quarter vs prior year+2.4%+12.3%+8.8%
EPS Growth (YoY)Latest quarter vs prior year0.0%+81.8%-100.0%-11.9%
MDT leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

IART leads this category, winning 4 of 5 comparable metrics.

On an enterprise value basis, IART's 13.0x EV/EBITDA is more attractive than MDT's 14.3x.

MetricDRTS logoDRTSAlpha Tau Medical…IART logoIARTIntegra LifeScien…NVCR logoNVCRNovoCure LimitedMDT logoMDTMedtronic plc
Market CapShares × price$691M$1.1B$1.9B$99.9B
Enterprise ValueMkt cap + debt − cash$689M$2.9B$2.1B$126.2B
Trailing P/EPrice ÷ TTM EPS-14.81x-2.01x-13.80x21.60x
Forward P/EPrice ÷ next-FY EPS est.5.77x14.13x
PEG RatioP/E ÷ EPS growth rate36.00x
EV / EBITDAEnterprise value multiple13.01x14.32x
Price / SalesMarket cap ÷ Revenue0.65x2.92x2.98x
Price / BookPrice ÷ Book value/share8.20x1.00x5.51x2.08x
Price / FCFMarket cap ÷ FCF19.28x
IART leads this category, winning 4 of 5 comparable metrics.

Profitability & Efficiency

MDT leads this category, winning 6 of 9 comparable metrics.

MDT delivers a 9.4% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-57 for DRTS. DRTS carries lower financial leverage with a 0.18x debt-to-equity ratio, signaling a more conservative balance sheet compared to IART's 1.95x. On the Piotroski fundamental quality scale (0–9), MDT scores 6/9 vs DRTS's 3/9, reflecting solid financial health.

MetricDRTS logoDRTSAlpha Tau Medical…IART logoIARTIntegra LifeScien…NVCR logoNVCRNovoCure LimitedMDT logoMDTMedtronic plc
ROE (TTM)Return on equity-57.3%-47.6%-50.8%+9.4%
ROA (TTM)Return on assets-42.3%-13.7%-16.5%+175.8%
ROICReturn on invested capital-46.5%+1.7%-16.4%+6.0%
ROCEReturn on capital employed-48.7%+2.2%-28.9%+7.5%
Piotroski ScoreFundamental quality 0–93556
Debt / EquityFinancial leverage0.18x1.95x0.85x0.59x
Net DebtTotal debt minus cash-$2M$1.8B$187M$26.3B
Cash & Equiv.Liquid assets$16M$235M$103M$2.2B
Total DebtShort + long-term debt$14M$2.0B$290M$28.5B
Interest CoverageEBIT ÷ Interest expense-100.93x-10.36x-96.80x9.08x
MDT leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

DRTS leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in DRTS five years ago would be worth $8,084 today (with dividends reinvested), compared to $875 for NVCR. Over the past 12 months, DRTS leads with a +188.6% total return vs MDT's -2.8%. The 3-year compound annual growth rate (CAGR) favors DRTS at 35.6% vs NVCR's -37.6% — a key indicator of consistent wealth creation.

MetricDRTS logoDRTSAlpha Tau Medical…IART logoIARTIntegra LifeScien…NVCR logoNVCRNovoCure LimitedMDT logoMDTMedtronic plc
YTD ReturnYear-to-date+62.5%+12.9%+28.3%-18.1%
1-Year ReturnPast 12 months+188.6%+6.5%+1.1%-2.8%
3-Year ReturnCumulative with dividends+149.2%-73.1%-75.7%-4.2%
5-Year ReturnCumulative with dividends-19.2%-81.7%-91.3%-27.7%
10-Year ReturnCumulative with dividends-22.3%-63.0%+30.3%+26.5%
CAGR (3Y)Annualised 3-year return+35.6%-35.4%-37.6%-1.4%
DRTS leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

Evenly matched — DRTS and MDT each lead in 1 of 2 comparable metrics.

MDT is the less volatile stock with a 0.47 beta — it tends to amplify market swings less than IART's 2.34 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DRTS currently trades 86.5% from its 52-week high vs MDT's 73.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricDRTS logoDRTSAlpha Tau Medical…IART logoIARTIntegra LifeScien…NVCR logoNVCRNovoCure LimitedMDT logoMDTMedtronic plc
Beta (5Y)Sensitivity to S&P 5001.72x2.34x2.20x0.47x
52-Week HighHighest price in past year$9.07$16.49$20.06$106.33
52-Week LowLowest price in past year$2.57$8.70$9.82$77.16
% of 52W HighCurrent price vs 52-week peak+86.5%+82.2%+83.9%+73.3%
RSI (14)Momentum oscillator 0–10049.475.969.827.3
Avg Volume (50D)Average daily shares traded328K858K1.5M7.8M
Evenly matched — DRTS and MDT each lead in 1 of 2 comparable metrics.

Analyst Outlook

MDT leads this category, winning 1 of 1 comparable metric.

Analyst consensus: DRTS as "Buy", IART as "Buy", NVCR as "Buy", MDT as "Buy". Consensus price targets imply 99.0% upside for NVCR (target: $34) vs -11.5% for IART (target: $12). MDT is the only dividend payer here at 3.57% yield — a key consideration for income-focused portfolios.

MetricDRTS logoDRTSAlpha Tau Medical…IART logoIARTIntegra LifeScien…NVCR logoNVCRNovoCure LimitedMDT logoMDTMedtronic plc
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuy
Price TargetConsensus 12-month target$12.00$12.00$33.50$109.50
# AnalystsCovering analysts4261549
Dividend YieldAnnual dividend ÷ price+3.6%
Dividend StreakConsecutive years of raises036
Dividend / ShareAnnual DPS$2.78
Buyback YieldShare repurchases ÷ mkt cap0.0%+0.0%0.0%+3.2%
MDT leads this category, winning 1 of 1 comparable metric.
Key Takeaway

MDT leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). IART leads in 1 (Valuation Metrics). 1 tied.

Best OverallMedtronic plc (MDT)Leads 3 of 6 categories
Loading custom metrics...

DRTS vs IART vs NVCR vs MDT: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is DRTS or IART or NVCR or MDT a better buy right now?

For growth investors, NovoCure Limited (NVCR) is the stronger pick with 8.

3% revenue growth year-over-year, versus 1. 5% for Integra LifeSciences Holdings Corporation (IART). Medtronic plc (MDT) offers the better valuation at 21. 6x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate Alpha Tau Medical Ltd. (DRTS) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — DRTS or IART or NVCR or MDT?

On forward P/E, Integra LifeSciences Holdings Corporation is actually cheaper at 5.

8x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — DRTS or IART or NVCR or MDT?

Over the past 5 years, Alpha Tau Medical Ltd.

(DRTS) delivered a total return of -19. 2%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: NVCR returned +30. 3% versus IART's -63. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — DRTS or IART or NVCR or MDT?

By beta (market sensitivity over 5 years), Medtronic plc (MDT) is the lower-risk stock at 0.

47β versus Integra LifeSciences Holdings Corporation's 2. 34β — meaning IART is approximately 402% more volatile than MDT relative to the S&P 500. On balance sheet safety, Alpha Tau Medical Ltd. (DRTS) carries a lower debt/equity ratio of 18% versus 195% for Integra LifeSciences Holdings Corporation — giving it more financial flexibility in a downturn.

05

Which is growing faster — DRTS or IART or NVCR or MDT?

By revenue growth (latest reported year), NovoCure Limited (NVCR) is pulling ahead at 8.

3% versus 1. 5% for Integra LifeSciences Holdings Corporation (IART). On earnings-per-share growth, the picture is similar: Medtronic plc grew EPS 30. 8% year-over-year, compared to -73. 6% for Integra LifeSciences Holdings Corporation. Over a 3-year CAGR, NVCR leads at 6. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — DRTS or IART or NVCR or MDT?

Medtronic plc (MDT) is the more profitable company, earning 13.

9% net margin versus -31. 6% for Integra LifeSciences Holdings Corporation — meaning it keeps 13. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MDT leads at 17. 8% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is DRTS or IART or NVCR or MDT more undervalued right now?

On forward earnings alone, Integra LifeSciences Holdings Corporation (IART) trades at 5.

8x forward P/E versus 14. 1x for Medtronic plc — 8. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.

08

Which pays a better dividend — DRTS or IART or NVCR or MDT?

In this comparison, MDT (3.

6% yield) pays a dividend. DRTS, IART, NVCR do not pay a meaningful dividend and should not be held primarily for income.

09

Is DRTS or IART or NVCR or MDT better for a retirement portfolio?

For long-horizon retirement investors, Medtronic plc (MDT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

47), 3. 6% yield). Integra LifeSciences Holdings Corporation (IART) carries a higher beta of 2. 34 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MDT: +26. 5%, IART: -63. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between DRTS and IART and NVCR and MDT?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: DRTS is a small-cap quality compounder stock; IART is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; MDT is a mid-cap income-oriented stock. MDT pays a dividend while DRTS, IART, NVCR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

DRTS

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

IART

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 23%
Run This Screen
Stocks Like

NVCR

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 6%
  • Gross Margin > 45%
Run This Screen
Stocks Like

MDT

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 7%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.